NASDAQ, VNDA - Vanda Pharmaceuticals

We are a biopharmaceutical company focused on the development and  commercialization of clinical-stage drug candidates for central nervous system  disorders, with exclusive worldwide commercial rights to three product  candidates in clinical development. We believe that each of our product  candidates will address a large market with significant unmet medical needs by  offering advantages over currently available therapies. Our product portfolio  includes:  ? Fiaptatm (iloperidone), a compound for the treatment of schizophrenia and   bipolar disorder. On November 27, 2007 the United States Food and Drug   Administration (FDA) accepted a New Drug Application (NDA) for Fiaptatm for  the treatment of schizophrenia. Acceptance of the NDA confirms that the   application is sufficiently complete for FDA review.  ...

Sector:	Consumer Durables
Industry:	Major Pharmaceuticals
P/E Ratio:	25
PEG Ratio:	N/A
EPS:	N/A
DivYield:	N/A
PtB:	0.5762
PtS:	4.05
EBITDA:	N/A
Shares:	58.93M
Market Cap:	247.52M
52wk range:	3.81 - 5.55

216.73.216.229
United States